A game changer for Americans who can't afford these drugs otherwise.
In the final weeks of his presidency, Joe Biden moved to reframe obesity as a treatable disease rather than a personal failing — proposing that Medicare and Medicaid cover powerful new weight-loss drugs for millions of Americans who could not otherwise afford them. The gesture is sweeping in its ambition, promising relief to some 7.5 million beneficiaries at a projected cost of $35 billion over a decade, yet it arrives at a moment of political transition that may determine whether it ever takes effect. At its core, the debate is not merely about drug coverage, but about how a society chooses to understand suffering — whether through the lens of medicine, personal responsibility, or the deeper structures that shape how people eat and live.
- Drugs that cost over $1,000 a month have remained out of reach for most Americans, and the Biden administration's final-stretch proposal attempts to close that gap before power changes hands.
- The sheer scale of the eligible population — potentially 28 million Medicaid recipients meeting the clinical definition of obesity — reveals just how vast and unaddressed the crisis has become.
- RFK Jr., tapped to lead the very agency that would implement this rule, has openly opposed it, arguing the billions would be better spent on organic food and gym memberships than pharmaceutical injections.
- The incoming Trump administration's emphasis on cutting government spending puts a $35 billion, decade-long commitment in immediate political jeopardy.
- The rule's fate now rests on Senate confirmation battles, administrative discretion, and whether a new government will honor a reframing of obesity as disease rather than choice.
On a Tuesday morning in late November, the Biden administration proposed what could be one of its most consequential health policy moves: extending Medicare and Medicaid coverage to expensive weight-loss drugs like Wegovy and Ozempic. The rule, issued by the Department of Health and Human Services, would make an estimated 3.5 million Medicare beneficiaries and 4 million Medicaid recipients eligible for medications that can help users lose 15 to 25 percent of their body weight through weekly injections. At roughly $1,000 to $1,300 per month, these drugs have been largely inaccessible to anyone without private insurance coverage.
The financial commitment is significant — up to $35 billion over ten years — but proponents argue the investment would ultimately save money by preventing costly obesity-related conditions like diabetes, heart disease, and stroke. HHS Secretary Xavier Becerra called it a game changer for Americans who have been priced out of treatment. The proposal also carries a symbolic weight: it reframes obesity as a disease deserving medical intervention, working around a longstanding legal prohibition on Medicare covering weight-loss products.
The proposal's survival, however, is far from certain. Robert F. Kennedy Jr., Trump's nominee to lead HHS, has been a vocal critic of covering these drugs through public programs. He has argued instead for directing funds toward better nutrition and physical activity, suggesting that for roughly half the cost of Ozempic coverage, the government could provide every obese American with organic meals and a gym membership. His confirmation and the incoming administration's broader appetite for spending cuts could effectively shelve the rule before it ever takes hold — leaving millions of Americans waiting to see whether access to these drugs becomes a matter of policy or continued privilege.
On a Tuesday morning in late November, the Biden administration released a proposal that would fundamentally reshape who gets access to the most expensive weight-loss drugs on the market. Under the new rule from the Department of Health and Human Services, millions of Americans struggling with obesity would become eligible for Medicare or Medicaid coverage of medications like Wegovy and Ozempic—drugs that have become synonymous with rapid, dramatic weight loss and have attracted everyone from celebrities to people desperate for medical intervention.
The scale of the potential shift is enormous. The administration estimates that 3.5 million additional Medicare beneficiaries and 4 million Medicaid recipients could qualify for coverage. Yet those numbers may understate the true eligible population. The Centers for Medicare and Medicaid Services has calculated that roughly 28 million people on Medicaid alone meet the clinical definition of obesity. The drugs themselves are remarkable in their effect: users can shed 15 to 25 percent of their body weight by taking weekly injections that essentially trick the brain into feeling full. Novo Nordisk's Wegovy costs around $1,300 per month. Eli Lilly's Zepbound runs about $1,000. For most Americans without insurance coverage, these prices have been prohibitive.
The financial commitment is substantial. Taxpayers would shoulder as much as $35 billion over the next decade to make these medications available through public insurance programs. Health and Human Services Secretary Xavier Becerra framed the move as a moral imperative, telling the Associated Press that it represented "a game changer for Americans who can't afford these drugs otherwise." A bipartisan group of lawmakers had already been pushing for exactly this kind of coverage, arguing that preventing obesity-related complications—diabetes, heart disease, stroke—would ultimately save the government far more money than the upfront cost of the medications.
But the proposal faces a formidable obstacle. Robert F. Kennedy Jr., Trump's nominee to lead the HHS, has been a vocal opponent of covering these drugs through government programs. Kennedy has argued that the money would be better spent on what he sees as the root cause of obesity: poor nutrition and sedentary lifestyles. In remarks to federal lawmakers earlier in the year, he proposed an alternative: "For half the price of Ozempic, we could purchase regeneratively raised, organic food for every American, three meals a day and a gym membership, for every obese American." His position reflects a fundamentally different philosophy about how to address weight and health—one that emphasizes prevention and lifestyle change over pharmaceutical intervention.
The rule itself works around a decades-old legal barrier. Medicare has long been prohibited from covering weight-loss products, a restriction rooted in the idea that obesity was a lifestyle issue rather than a treatable medical condition. The Biden proposal reframes obesity as a disease, which would allow the government insurance program to cover medications designed to treat it. Some people already receive coverage for these drugs through Medicare or Medicaid if they have diabetes or are at high risk for cardiovascular events, but the new rule would expand eligibility based solely on obesity diagnosis.
What happens next depends on political forces beyond the Biden administration's control. Kennedy must be confirmed by the Senate to lead HHS, and once in office, he would have significant authority over how—or whether—the rule gets implemented. Trump himself has not taken a clear public position on the coverage question, but his allies and Cabinet nominees have emphasized cutting government spending. The expensive price tag of the proposal could prove vulnerable to that scrutiny. The weight-loss drug market itself has been constrained by supply shortages, which have only reinforced their status as scarce, expensive commodities available mainly to the wealthy. Whether millions of ordinary Americans will actually get access to these medications depends on whether the incoming administration chooses to let this rule take effect.
Citas Notables
It's a game changer for Americans who can't afford these drugs otherwise.— HHS Secretary Xavier Becerra
For half the price of Ozempic, we could purchase regeneratively raised, organic food for every American, three meals a day and a gym membership, for every obese American.— Robert F. Kennedy Jr.
La Conversación del Hearth Otra perspectiva de la historia
Why does the Biden administration think now is the right moment to push this through?
They're operating on the assumption that obesity is a disease with a medical solution, and that the long-term savings from preventing complications justify the upfront cost. They also know the window is closing—once Trump takes office, the political calculus changes entirely.
And Kennedy's alternative—subsidizing food and gym memberships instead—that's not actually cheaper?
He claims it would cost half as much. But that's a different kind of intervention. It assumes people have the knowledge, discipline, and access to use those resources effectively. The drugs work regardless of those factors. They're a shortcut, which is why some people call them miracle drugs and others see them as a symptom of a broken food system.
So the real fight is about what obesity actually is?
Partly. But it's also about what government should pay for. Kennedy sees it as a lifestyle problem that shouldn't be subsidized. The administration sees it as a medical condition that costs the system more money if left untreated. Both arguments have logic behind them.
What happens if Kennedy blocks this after he's confirmed?
The rule would likely be rescinded or never fully implemented. The administration can propose it, but the incoming HHS secretary has enormous power over how federal health programs operate. Kennedy could simply choose not to enforce it.
And the people who were counting on access?
They'd be back where they started—unable to afford the drugs unless they have private insurance or a lot of money. The shortages would probably continue. The wealthy would keep using them, and everyone else would be left with the alternatives Kennedy prefers, whether or not those alternatives actually work for them.